AstraZeneca PLC is one step further along the road to returning its PD-L1 inhibitor Imfinzi to the bladder cancer market following success in the Phase III NIAGARA trial that looked at its use peri-operatively in muscle-invasive patients eligible for surgery.
ESMO 24: NIAGARA – Trial Design Question Hangs Over Imfinzi’s Bladder Cancer Return
AstraZeneca’s NIAGARA trial of perioperative Imfinzi in bladder cancer was positively received at the ESMO meeting but its design did not distinguish the contributions of each treatment portion to the overall effect – something that the US FDA is likely to have a view on.
